AMY-101

DRUG3 trials

Sponsors

Amyndas Pharmaceuticals S.A.

Conditions

Acute Respiratory Distress Syndrome Due to SARS-CoV-2 Infection (Severe COVID19)Complement Mediated DiseasesGingivitis

Phase 1

First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers

CompletedNCT03316521

Amyndas Pharmaceuticals S.A.Complement Mediated Diseases

Start: 2017-04-24End: 2017-11-30Updated: 2018-01-16

A Study of the C3 Complement Inhibitor AMY-101 in Adults With Gingivitis

CompletedNCT03694444

Amyndas Pharmaceuticals S.A.Gingivitis

Start: 2019-07-22End: 2020-10-30Updated: 2021-02-21

Phase 2

A Study of the C3 Inhibitor AMY-101 in Patients With ARDS Due to COVID-19 (SAVE)

Amyndas Pharmaceuticals S.A.Acute Respiratory Distress Syndrome Due to SARS-CoV-2 Infection (Severe COVID19)

Start: 2021-09-30End: 2022-12-31Target: 144Updated: 2021-02-21

Related Papers

Phase IIa clinical trial of complement C3 inhibitor AMY-101 in adults with periodontal inflammation

Journal of Clinical Investigation2021-10-0767 citations

Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial.

2020-09-28149 citations